10 citations
,
October 2015 in “Medicina Clínica (english Edition)” Recombinant human epidermal growth factor is versatile, effective, and safe for long-term skin and mucosal treatments.
8 citations
,
March 2019 in “Drugs - Real World Outcomes” Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
March 2026 in “Journal for ImmunoTherapy of Cancer” Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
34 citations
,
July 2011 in “International journal of pharmaceutics” Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.
Ion sequential therapy improves heart function after a heart attack.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
December 2025 in “Pharmaceutics” EV-based drug delivery shows promise but faces challenges in standardization and scalability.
3 citations
,
May 2019 in “Cytotherapy” ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.
Developing microRNA-based treatments is hard but has potential.
November 2023 in “Research Square (Research Square)” NIR-II imaging effectively tracked stem cells that helped repair facial nerve defects in rats.
30 citations
,
December 2019 in “PLoS ONE” The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair growth cells and aiding self-repair.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
4 citations
,
March 2012 in “Annals of oncology” New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.
2 citations
,
June 1985 in “PubMed” Ethylenthiourea is toxic to the liver and nervous system, especially with alcohol.
September 2020 in “Acta Scientific Cancer Biology” Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.
41 citations
,
November 2024 in “Molecular Biomedicine” Engineered extracellular vesicles show promise for targeted therapy but need more research for clinical use.
November 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair cells.
17 citations
,
April 2016 in “Journal of Investigative Dermatology” KB2115 (eprotirome) can safely extend the hair growth phase without damaging cells or changing hair color.
168 citations
,
December 1986 in “Cancer Chemotherapy and Pharmacology” Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.
September 2023 in “Journal of the American Academy of Dermatology”
77 citations
,
August 2025 in “Signal Transduction and Targeted Therapy” Extracellular vesicles show promise for treating diseases but face challenges in development and regulation.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
15 citations
,
March 2012 in “International journal of nanomedicine” Local injections of nanosized rhEPO can speed up skin healing and improve quality after deep second-degree burns.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine” 23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.